drugset / Trial / NCT06166992

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

NCT06166992

Phase 1 Completed 14 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main objective of this trial is to investigate the absolute bioavailability of BI 1291583 (test treatment T, not radio-labelled) compared with BI 1291583 (C-14) (reference treatment R).

Timeline

Start
2023-12-12
Primary completion
2024-02-07
Completion
2024-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown

Indications

No indication recorded.